

PATENT
ATTORNEY DOCKET NO. 50216/003004

Certificate of Mailing	
Date of Deposit <u>7/31/01</u>	Label Number: <u>EL 834597195 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>Guy Beardsley</u> Printed name of person mailing correspondence	<u>Guy Beardsley</u> Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gerald Krystal et al. Art Unit: Not yet assigned
Serial No.: Not yet assigned Examiner: Not yet assigned
Filed: July 31, 2001 Customer No.: 21559
Title: PEPTIDES AND THEIR USE TO AMELIORATE CELL DEATH

Assistant Commissioner For Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.821

As part of the patent application filed herewith, enclosed is a sequence listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825 and consisting of six pages.

As required by 37 C.F.R. § 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney. Each sequence in the application appears separately in the sequence listing. And each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of

the sequence listing in computer readable form.


As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.


As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: July 31, 2001


Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109


Paul T. Clark
30,162

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

\\\Clark-w2k1\documents\50216\50216.003004 Sequence Statement.wpd



21559

PATENT TRADEMARK OFFICE

SEQUENCE LISTING

<110> Krystal, Gerald
Rabkin, Simon W.

<120> Peptides and Their Use to Ameliorate
Cell Death

<130> 50216/003004

<150> US 09/294,457
<151> 1999-04-19

<150> US 08/759,599
<151> 1996-12-05

<150> US 60/008,233
<151> 1995-12-06

<160> 16

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 1
Ser Val Asp Val Glu Tyr
1 5

<210> 2
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 2
Tyr Val Asp Val Asp Thr
1 5

<210> 3
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 3
Thr Val Asp Val Glu Tyr
1 5

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 4
Tyr Val Asp Val Asp Thr Asn Glu Leu Leu Lys
1 5 10

<210> 5
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 5
Ser Val Asp Val Glu Tyr Thr Val Gln Phe Thr Pro Leu Asn Pro Asp
1 5 10 15

<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 6
Ser Val Asp Val Glu Tyr Thr Gln Phe Thr Asp Phe Arg Gly Lys Leu
1 5 10 15
Thr Lys Leu Leu
20

<210> 7
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 7
Ser Val Asp Val Glu Tyr Thr Val Gln Phe Thr Pro Leu Asn Pro Asp
1 5 10 15
Asp Asp Phe Arg Pro

<210> 8
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 8
Tyr Val Asp Val Asp Thr Asn Glu Leu Leu Lys Ser Glu Gln Leu Leu
1 5 10 15
Thr Ala Ser Glu
20

<210> 9
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 9
Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg
1 5 10 15
Thr Gly Asp Arg
20

<210> 10
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 10
Arg Leu Ile Leu Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala
1 5 10 15
Lys Glu Ala Glu
20

<210> 11
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 11
Glu Val Thr Glu Glu Glu Glu Thr Val Pro Leu Lys Thr Leu Glu Ala

1 5 10 15
Met Ile Asp Glu
20

<210> 12
<211> 413
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 12
Ile Ala Gly Pro Glu Trp Leu Leu Asp Arg Pro Ser Val Asn Asn Ser
1 5 10 15
Gln Leu Val Val Ser Val Ala Gly Thr Val Gly Thr Asn Gln Asp Ile
20 25 30
Ser Leu Lys Phe Phe Glu Ile Asp Leu Thr Ser Arg Pro Ala His Gly
35 40 45
Gly Lys Thr Glu Gln Gly Leu Ser Pro Lys Ser Lys Pro Phe Ala Thr
50 55 60
Asp Ser Gly Ala Met Ser His Lys Leu Glu Lys Ala Asp Leu Leu Lys
65 70 75 80
Ala Ile Gln Glu Gln Leu Ile Ala Asn Val His Ser Asn Asp Asp Tyr
85 90 95
Phe Glu Val Ile Asp Phe Ala Ser Asp Ala Thr Ile Thr Asp Arg Asn
100 105 110
Gly Lys Val Tyr Phe Ala Asp Lys Asp Gly Ser Val Thr Leu Pro Thr
115 120 125
Gln Pro Val Gln Glu Phe Leu Leu Ser Gly His Val Arg Val Arg Pro
130 135 140
Tyr Lys Glu Lys Pro Ile Gln Asn Gln Ala Lys Ser Val Asp Val Glu
145 150 155 160
Tyr Thr Val Gln Phe Thr Pro Leu Asn Pro Asp Asp Asp Phe Arg Pro
165 170 175
Gly Leu Lys Leu Thr Lys Leu Leu Lys Thr Leu Ala Ile Gly Asp Thr
180 185 190
Ile Thr Ser Gln Glu Leu Leu Ala Gln Ser Ile Leu Asn Lys
195 200 205
Asn His Pro Gly Tyr Thr Ile Tyr Glu Arg Asp Ser Ser Ile Val Thr
210 215 220
His Asp Asn Asp Ile Phe Arg Thr Ile Leu Pro Met Asp Gln Glu Phe
225 230 235 240
Thr Tyr Arg Val Lys Asn Arg Glu Gln Ala Tyr Arg Ile Asn Lys Lys
245 250 255
Ser Gly Leu Asn Glu Glu Ile Asn Asn Thr Asp Leu Ile Ser Leu Glu
260 265 270
Tyr Lys Tyr Val Leu Lys Lys Gly Glu Lys Pro Tyr Asp Pro Phe Asp
275 280 285
Arg Ser His Leu Lys Leu Phe Thr Ile Lys Tyr Val Asp Val Asp Thr
290 295 300
Asn Glu Leu Leu Lys Ser Glu Gln Leu Leu Thr Ala Ser Glu Arg Asn
305 310 315 320
Leu Asp Phe Arg Asp Leu Tyr Asp Pro Arg Asp Lys Ala Lys Leu Leu
325 330 335
Tyr Asn Asn Leu Asp Ala Phe Gly Ile Met Asp Tyr Thr Leu Thr Gly
340 345 350

Lys Val Glu Asp Asn His Asp Asp Thr Asn Arg Ile Ile Thr Val Tyr
355 360 365
Met Gly Lys Arg Pro Glu Gly Glu Asn Ala Ser Tyr His Ala Tyr Asp
370 375 380
Lys Asp Arg Tyr Thr Glu Glu Glu Arg Glu Val Tyr Ser Tyr Leu Arg
385 390 395 400
Tyr Thr Gly Thr Pro Ile Pro Asp Asn Pro Asp Asp Lys
405 410

<210> 13
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<221> VARIANT
<222> 1
<223> Xaa=Ser or Tyr

<400> 13
Xaa Val Asp Val
1

<210> 14
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<221> VARIANT
<222> 4
<223> Xaa=Glu or Asp

<400> 14
Val Asp Val Xaa
1

<210> 15
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<221> VARIANT
<222> 1
<223> Xaa=Ser or Tyr

<221> VARIANT
<222> 5

<223> Xaa=Glu or Asp

<400> 15

Xaa Val Asp Val Xaa
1 5

<210> 16

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polypeptide

<221> VARIANT

<222> 4

<223> Xaa=Glu or Asp

<221> VARIANT

<222> 5

<223> Xaa=Tyr or Thr

<400> 16

Val Asp Val Xaa Xaa
1 5